Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Background:
Ovarian carcinoma is extremely sensitive to (platinum-based) chemotherapy; however, most patients will relapse with platinum-resistant disease, badly affecting their prognosis. Effective therapies for relapsing resistant tumors are urgently needed.
Methods:
We used patient-derived xenografts (PDXs) of ovarian carcinoma resistan...
Alternative Titles
Full title
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_80db0ecc1ec54ad8afae436bdf40fe99
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_80db0ecc1ec54ad8afae436bdf40fe99
Other Identifiers
ISSN
1758-8359,1758-8340
E-ISSN
1758-8359
DOI
10.1177/17588359221095064
